TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Tender joint counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Swollen joint counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time spent at moderate-intensity physical activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Resistance to facemask
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to full oral feeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rates of tachypnoea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: overall work-related stress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: role stress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: personal strain
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Spontaneous labour
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Agreement between triage methods
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Admission rates
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Coagulation time (CT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Clot formation time (CFT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Maximum clot firmness (MCF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: adverse cardiometabolic outcomes
Endpoint domain: Adverse events/effects
Primary endpoint: cancer
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction in flatus incontinence episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adherence levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical benefit from study therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of postoperative sore throat (POST)
Endpoint domain: Adverse events/effects
Primary endpoint: Intraoperative stone-free rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median CDAI scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total polyunsaturated fatty acid contents in high-density lipoprotein phospholipids
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy at 6 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Spontaneous complete miscarriage after 7 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Operative Time (MOT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Mean Total Operative Time (TOT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: duration of grade ≥2 mucositis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: body weight loss during RT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of grade 3 mucositis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vitreous VEGF concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of torque development
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intraocular pressure (IOP) increases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: serum concentrations of total IGF‐I
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: average pain unpleasantness ratings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: peak pain unpleasantness ratings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of transfusions per patient
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Median cost to the hospital per patient
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: TRL-apolipoprotein B48 production
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time for skin closure
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Cost of each device
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Reduction in serum PSA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stable PSA for at least 12 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cerebrovascular disease
Endpoint domain: Mortality/survival
Primary endpoint: Total cancer
Endpoint domain: Mortality/survival
Primary endpoint: Bone fractures
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of participants with malaria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Baseline-corrected anti-GMZ2 antibody concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: originality
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: out-of-the-boxness
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: maintained clinical response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total occlusion of varicose veins
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reduction of non-injection drug use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plantar flexion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Radiation exposure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Adherence to online exercises
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of the lower lid marginal conjunctiva
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lower lid margin staining
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: decreased infant episodes of respiratory illness with fever
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: mean concentration of nitric oxide metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: median HRV during surfactant administration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TREC concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative complications rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Carotid stenosis reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Major complications (death/stroke)
Endpoint domain: Mortality/survival
Primary endpoint: Return to full activity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: relapse-free interval (pRFI) of 5 years
Endpoint domain: Mortality/survival
Primary endpoint: MPN symptoms improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean plasma glucose increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Plasma insulin increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean increase in erosion score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Fewer adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of patients free from symptomatic GSV reflux at 8 years
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of absence of GSV reflux at 8 years
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Venous Clinical Severity Score (VCSS) after 8 years
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maternal serum concentrations of NO
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: RBG
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of Oratest stain to oral carcinoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Sensitivity of Oratest stain to dysplasia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Alanon attendance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Use of AA-related skills
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: minutes/night of usage
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Plasma zinc concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: success rate of ECV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: median time to recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: sensory deficit in the IBN area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: shoulder pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: FIT completion rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion with 24-week HIV-1 RNA <50 copies/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Attendance at least 1 nonemergency clinic visit by week 6 postrelease
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Reported not missing any antiretroviral doses in the past 30 days at week 24
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Interventricular septum area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of participants who stopped waterpipe use
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: RSV hospitalizations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: total days of RSV hospitalization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: total RSV hospital days with increased supplemental oxygen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: total motor scores improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: daily off-time reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gene expression of proinflammatory parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: smaller increase in serum P
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Bone Turnover Markers (BTM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity for detecting acute fractures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity for detecting acute fractures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Interobserver agreement (kappa)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-operative nausea and vomiting
Endpoint domain: Adverse events/effects
Primary endpoint: Total effectiveness category difference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TNF levels in synovial fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in ultimate strength values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Surface degradation of elastomeric ligatures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: No antibiotic use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Satisfaction with the visit
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: slow component of VO2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of suprahyoid muscles activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Latency between onset and peak amplitude of suprahyoid muscles activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in DNA methylation at CpG sites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VCAM values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: urinary cGMP excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: induction-to-vaginal delivery interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Incidence and severity of oral mucositis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effective mask ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Chest rise visibility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Endoscopic/histologic healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Total GERD Symptoms and Severity score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative PCA remifentanil consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: GSS improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Febrile seizure recurrence
Endpoint domain: Mortality/survival
Primary endpoint: global score improvement
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Knowledge and competence
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Complications requiring aftercare
Endpoint domain: Adverse events/effects
Primary endpoint: Subjective denture perception
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Glucose plasma level improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Rates of abstinence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Nervous function defect improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: percentage of umbilical cord blood placental alkaline phosphatase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ASC responses to pneumococcal polysaccharides
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Salivary IgA responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Increased serum concentrations of IgG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Leg lean mass increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: O(2) flux per ATP(max)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Attentional abilities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decision-making appropriateness
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: days of nausea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: days of vomiting
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: wake-up quality
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: FVIII activity increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Activated partial prothrombin time decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Protein C pathway activity decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: undetectable HIV-1 RNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: short-interval intra-cortical inhibition (SICI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: intra-cortical facilitation (ICF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Elevated Edinburgh Postnatal Depression Scale (EPDS) scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Mental health outcomes
Primary endpoint: Perceived difficulty 'making ends meet'
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Return to activities of daily living
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: pain reduction in neck, shoulder, elbow, and wrist
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 90-day risk of ischemic stroke
Endpoint domain: Mortality/survival
Primary endpoint: percent ventricular pacing (VP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: restricted extension of the ankle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: atrophy of lower limbs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Improvement in sensory functions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: tolerability of perampanel
Endpoint domain: Adverse events/effects
Primary endpoint: proportion of patients with moderate to severe depression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mEASI mAUC as a percentage of baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: incidence of transient skin burning
Endpoint domain: Adverse events/effects
Primary endpoint: metabolic features
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: hepatic features
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: urethral stricture recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clinical outcome 12 months after aSAH
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 15D health‐related quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: motor abilities improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VO2, VCO2, and VT at peak effort
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Website utilization
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Increase in corneometer values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Reduction in transepidermal water loss (TEWL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Differences in total and percentage of wrinkle areas
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Dialysis initiation
Endpoint domain: Mortality/survival
Primary endpoint: Composite end-point
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reproducibility of tests for LMC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sliding measurement for detecting SUI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rise in proinflammatory cytokine TNF-alpha
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Decrease in anti-inflammatory cytokine IL-10
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Rise in TNF/IL-10 ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Altered myocardial redox patterns
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in BDI-II score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in BAI score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: decrease in CTX‐I
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: decrease in CTX‐I:OC ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: reduction in MMP‐3 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Removal success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time for face-mask removal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Range of motion during face-mask removal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average perceived difficulty (RPE)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status